Orthopedic CME Center | OrthoSuperSite.com

Welcome, Guest

ORTHOSupersite Home

Upcoming Live Events

Orthopedic CME Activities

Show: All Journal Monograph Multimedia


	The Use of Spinal Osteotomy in the Treatment of Spinal Deformity
	Author(s)/Faculty: Patrick F. Bergin, MD; Joseph R. O’Brien, MD, MPH; Lauren E. Matteini, MD; Warren D. Yu, more MD; Khaled M. Kebaish, MD
	Source: Orthopedics 33:8	Type: Journal	Number of Articles: 1
	Release Date: August 2010	Expiration Date: August 31, 2011	Cost: $0.00 / $15.00 /$49.00
	Credit Type: CME	Number of Credit(s): 1.00	Provider:
	OVERVIEW Careful assessment of spinal deformities is essential in planning surgical treatment. Once a deformity is defined, a surgical plan should be constructed considering the degree of correction needed, the character of the deformity, and prior surgical history. Spinal osteotomies offer the ability to correct disabling, painful deformities; however, avoiding complications is the key to a successful outcome.


	Control the Bleeding, Control the Pain: New Therapeutic Advances
	Author(s)/Faculty: Fred Cushner, MD; Terese T. Horlocker, MD; Carl A. Deirmengian, MD; Jeffrey D. Swenson, more MD; Richard J. Friedman, MD, FRCSC; Keith R. Berend, MD
	Source:	Type: Multimedia	Number of Articles: 6
	Release Date: August 2010	Expiration Date: August 31, 2012	Cost: $0.00 / $0.00
	Credit Type: CME	Number of Credit(s): 2.00	Provider:
	OVERVIEW Target Audience: This CME activity is intended for orthopedic surgeons, anesthesiologists and other healthcare professionals involved in the care of patients undergoing total joint arthroplasty. CME Instructions: This CME activity consists of written materials, tables and figures, a post-test, and an evaluation. Completion of the activity for credit is done online at http://jeffline.jefferson.edu/jeffcme/vte/postconf Start by reviewing these instructions. Then, review the learning objectives to determine if the content relates to your individual learning needs, and note the conflict of interest disclosures and acknowledgement of commercial support. Next, proceed to view the CME activity material carefully, paying particular attention to the figures and the tables. After viewing the material, complete the CME process online at http://jeffline.jefferson.edu/jeffcme/vte/postconf. Here you will register for credits, and complete both the post test and the CME Evaluation. A minimum score of 80 percent correct must be obtained in order for credit to be awarded. There is no fee for participation. Time needed to complete this activity is estimated at no more than two hours. Requests for credit must be completed before the expiration date indicated for the activity. No credit will be given after that date. CME/CE certificate requests cannot be processed if the evaluation portion is not complete. To be awarded credit, please be sure to complete both the post-test and the evaluation. Credit for this CME activity is available until July 31, 2012. Learning Objectives: After viewing the CME activity and completing the accompanying questions, the participant should be able to: Describe and critically review available data for existing therapies and novel anticoagulant agents in the prevention of venous thromboembolism (VTE) in addition to pain management (pre-, intra-, post-operative) Determine risk-benefit ratio of various therapeutic options Describe and be able to understand the application of novel approaches to pain management and VTE prevention Establish mechanisms for integrating public heath mandates and clinical guidelines into daily practice patterns. Understand how procedure selection and drug utilization effects patient outcomes regarding pain management, VTE incidence and occurrence of bleeding Disclosure: Jefferson Medical College endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines for Commercial Support. Every effort has been made to encourage faculty to disclose any commercial relationships or personal benefit with commercial companies whose products are discussed in the educational presentation. Disclosure of a relationship is not intended to suggest or condone bias in any presentations, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The individuals listed below have declared that they have no financial arrangements or affiliations with any corporate organization offering financial support or grant monies for this CME program or with any corporate organization whose product(s) will be discussed in their presentation(s): Jeanne G Cole, MS; Tara Fish; Terese Horlocker, MD The following individuals have declared financial interest(s) and/or affiliations: Keith R Berend, MD Consultant: Biomet; Salient Surgical; Synvasive Grant/Research Support: Biomet Product/Speakers’ Bureau: Biomet Fred Cushner, MD Consultant: sanofi-aventis; Astellas; Bayer Product/Speakers’ Bureau: sanofi-aventis Carl Deirmengian, MD Consultant: Synthes; Zimmer Scientific Advisor: Angiotech Stock Shareholder: CD Diagnostics Employee or Board Member: CD Diagnostics Richard J Friedman, MD Consultant: Astellas, Boehringer Ingelheim, Johnson & Johnson Grant Support: Boehringer Ingelheim, Johnson & Johnson Geno Merli, MD Consultant: sanofi-aventis; Bristol-Myers Squibb; Bayer; Ortho McNeil Grant/Research Support: sanofi-aventis; Boehringer Ingelheim; Bristol-Myers Squibb Product/Speakers’ Bureau: sanofi-aventis Scientific Advisor: Bristol-Myers Squibb; Bayer Other: sanofi-aventis Jeffrey Swenson, MD Product/Speakers’ Bureau: GE Medicals The following individual(s) have indicated that they will/may include discussion of investigational or off-label use of products. Richard J Friedman, MD Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education(ACCME) through the joint sponsorship of Jefferson Medical College and Thrombosis Education, Ltd. Jefferson Medical College of Thomas Jefferson University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Jefferson Medical College designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. How to retrieve your certificate: Credits earned for this activity can be retrieved online at the Jefferson Electronic Transcripts and Certificates site (http://jeffline.jefferson.edu/jeffcme/JeffETC/). Credits are posted to the JeffETC website weekly on Friday. Online transcripts are accessed using the combination of your last name plus last four digits of your SSN ["WebID"]. This WebID is created for you when you register for the module. If you have questions, please contact us at: Office of CME Jefferson Medical College of Thomas Jefferson University Jefferson Alumni Hall, Suite M5 1020 Locust St Philadelphia PA 19107 jeffersoncme@jefferson.edu 1 888 JEFF CME Commercial Support: Supported by an educational grant from PriCara® and Ortho-McNeil™, Divisions of Ortho-McNeil-Janssen Pharmaceuticals, Inc, administered by Ortho-McNeil Janssen Scientific Affairs, LLC


	Adolescent Patellofemoral Pain: A Review of Evidence for the Role of Lower Extremity Biomechanics and Core Instability
	Author(s)/Faculty: Patrick M. Carry, BA; Susan Kanai, PT; Nancy H. Miller, MD; John D. Polousky, MD more Patrick M. Carry, BA; Susan Kanai, PT; Nancy H. Miller, MD; John D. Polousky, MD
	Source: Orthopedics 33:7	Type: Journal	Number of Articles: 1
	Release Date: July 2010	Expiration Date: July 31, 2011	Cost: $0.00 / $15.00 /$49.00
	Credit Type: CME	Number of Credit(s): 1.00	Provider:
	OVERVIEW Adolescent idiopathic patellofemoral pain is a familiar but poorly understood diagnosis of exclusion, often used to describe a nonhomogeneous population of individuals suffering from the insidious onset of activity-related knee pain. Hip musculature weakness among symptomatic females has provided new evidence that a direct relationship may exist among decreased hip strength, altered femoral/pelvic mechanics, and patellofemoral pain.


	Current Concepts: Neonatal Brachial Plexus Palsy
	Author(s)/Faculty: Joshua M. Abzug, MD; Scott H. Kozin, MD more Joshua M. Abzug, MD; Scott H. Kozin, MD
	Source: Orthopedics 33:6	Type: Journal	Number of Articles: 1
	Release Date: June 2010	Expiration Date: June 30, 2011	Cost: $0.00 / $15.00 /$49.00
	Credit Type: CME	Number of Credit(s): 1.00	Provider:
	OVERVIEW Neonatal brachial plexus palsy continues to occur despite improvements in obstetric care. Recent research and published studies have focused on early and accurate diagnosis and a more precise prediction of outcome based on timing of muscle recovery. Reliable outcome measurements allow a better assessment of the natural history and the effect of various interventions. The precise surgical treatment algorithm to provide the best functional outcome is still evolving.


	Femoroacetabular Impingement and Acetabular Labral Tears
	Author(s)/Faculty: Lucas Rylander, MD; John M. Froelich, MD; Wendy Novicoff, PhD; Khaled Saleh, BSc, MD, more MSc, FRCS(C), MHCM
	Source: Orthopedics 33:5	Type: Journal	Number of Articles: 1
	Release Date: May 2010	Expiration Date: May 30, 2011	Cost: $0.00 / $15.00 /$49.00
	Credit Type: CME	Number of Credit(s): 1.00	Provider:
	OVERVIEW Labral tears have become closely linked with femoroacetabular impingement in the literature, and it is felt that true idiopathic labral tears are a rarity. Most “idiopathic” tears are secondary to FAI. Femoroacetabular impingement, in turn, has become accepted as a common disease entity that was previously unrecognized and misdiagnosed. This article reviews the pathoanatomy, treatment options, and outcomes associated with FAI and its potential influence on the development of “idiopathic” hip arthritis.


	The Perioperative Use of Disease-Modifying and Biologic Therapies in Patients With Rheumatoid Arthritis Undergoing Elective Orthopedic Surgery
	Author(s)/Faculty: Martin A. Lee, MRCP; Lyndon W. Mason, MRCS(Eng); Alexander L. Dodds, MRCS(Ed) more Martin A. Lee, MRCP; Lyndon W. Mason, MRCS(Eng); Alexander L. Dodds, MRCS(Ed)
	Source: ORTHOPEDICS 33:4	Type: Journal	Number of Articles: 1
	Release Date: April 2010	Expiration Date: April 30, 2011	Cost: $0.00 / $15.00 /$49.00
	Credit Type: CME	Number of Credit(s): 1.00	Provider:
	OVERVIEW Pre-, peri-, and postoperative guidelines have not been well established for the use of disease-modifying anti-rheumatic drugs (DMARDs) or biological therapies in rheumatoid arthritis. The current practice in the United Kingdom is that treatment with the DMARD methotrexate should not be stopped in patients whose disease is controlled prior to elective orthopedic procedures. In regard to biological therapies, due to the lack of human safety data, current British Society for Rheumatology guidelines suggest that TNF-a inhibitor therapy should be withheld for 2 to 4 weeks prior to any major surgical procedure.


	The Maisonneuve Injury: A Comprehensive Review
	Author(s)/Faculty: Craig S. Roberts MD;Bharati S. Kalyani MD;Peter V. Giannoudis MD, FRCS more Craig S. Roberts MD;Bharati S. Kalyani MD;Peter V. Giannoudis MD, FRCS
	Source: ORTHOPEDICS 33:3	Type: Journal	Number of Articles: 1
	Release Date: March 2010	Expiration Date: March 31, 2011	Cost: $0.00 / $15.00 /$49.00
	Credit Type: CME	Number of Credit(s): 1.00	Provider:
	OVERVIEW The Maisonneuve injury is a spiral fracture of the upper third of the fibula with disruption of the distal tibiofibular syndesmosis and associated injuries (eg, fracture of the medial malleolus, fracture of the posterior malleolus, and rupture of the deltoid ligament). The available evidence regarding its pathoanatomy, mechanism, treatment, implants used, complications, and functional outcome is limited. There is a need for prospective, multi-center studies on the Maisonneuve injury to better assess optimum treatment and long-term functional outcomes.


	Platelet-Rich Plasma: A Review of the Science and Possible Clinical Applications
	Author(s)/Faculty: Vishal Mehta, MD more Vishal Mehta, MD
	Source: ORTHOPEDICS 33:2	Type: Journal	Number of Articles: 1
	Release Date: February 2010	Expiration Date: February 28, 2011	Cost: $0.00 / $15.00 /$49.00
	Credit Type: CME	Number of Credit(s): 1.00	Provider:
	OVERVIEW Platelet-rich plasma is a new technology that may prove to have numerous applications in the treatment of musculoskeletal injuries. It has the ability to promote soft tissue healing in vitro and will likely provide improved healing in human trials as well. However, due to the paucity of human data, caution must be taken in its use in areas where only anecdotal evidence is available.

1
2
3